GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19033117 | Lung | IAC | regulation of mRNA metabolic process | 71/2061 | 288/18723 | 3.76e-11 | 1.24e-08 | 71 |
GO:00160556 | Lung | IAC | Wnt signaling pathway | 95/2061 | 444/18723 | 1.13e-10 | 2.80e-08 | 95 |
GO:01987386 | Lung | IAC | cell-cell signaling by wnt | 95/2061 | 446/18723 | 1.46e-10 | 3.48e-08 | 95 |
GO:00480248 | Lung | IAC | regulation of mRNA splicing, via spliceosome | 34/2061 | 101/18723 | 1.05e-09 | 1.95e-07 | 34 |
GO:00506847 | Lung | IAC | regulation of mRNA processing | 41/2061 | 137/18723 | 1.23e-09 | 2.15e-07 | 41 |
GO:00329708 | Lung | IAC | regulation of actin filament-based process | 77/2061 | 397/18723 | 4.85e-07 | 3.10e-05 | 77 |
GO:00064178 | Lung | IAC | regulation of translation | 86/2061 | 468/18723 | 1.16e-06 | 6.18e-05 | 86 |
GO:00329568 | Lung | IAC | regulation of actin cytoskeleton organization | 70/2061 | 358/18723 | 1.17e-06 | 6.20e-05 | 70 |
GO:00064027 | Lung | IAC | mRNA catabolic process | 50/2061 | 232/18723 | 2.28e-06 | 1.02e-04 | 50 |
GO:00072655 | Lung | IAC | Ras protein signal transduction | 65/2061 | 337/18723 | 4.48e-06 | 1.81e-04 | 65 |
GO:00605624 | Lung | IAC | epithelial tube morphogenesis | 63/2061 | 325/18723 | 5.28e-06 | 2.07e-04 | 63 |
GO:00434877 | Lung | IAC | regulation of RNA stability | 39/2061 | 170/18723 | 6.11e-06 | 2.29e-04 | 39 |
GO:00434887 | Lung | IAC | regulation of mRNA stability | 37/2061 | 158/18723 | 6.34e-06 | 2.32e-04 | 37 |
GO:19033135 | Lung | IAC | positive regulation of mRNA metabolic process | 30/2061 | 118/18723 | 8.36e-06 | 2.87e-04 | 30 |
GO:00610137 | Lung | IAC | regulation of mRNA catabolic process | 38/2061 | 166/18723 | 8.43e-06 | 2.87e-04 | 38 |
GO:00003817 | Lung | IAC | regulation of alternative mRNA splicing, via spliceosome | 19/2061 | 60/18723 | 1.36e-05 | 4.05e-04 | 19 |
GO:00610145 | Lung | IAC | positive regulation of mRNA catabolic process | 24/2061 | 87/18723 | 1.51e-05 | 4.45e-04 | 24 |
GO:00003807 | Lung | IAC | alternative mRNA splicing, via spliceosome | 22/2061 | 77/18723 | 1.85e-05 | 5.22e-04 | 22 |
GO:00064017 | Lung | IAC | RNA catabolic process | 54/2061 | 278/18723 | 2.27e-05 | 6.28e-04 | 54 |
GO:00611575 | Lung | IAC | mRNA destabilization | 23/2061 | 84/18723 | 2.57e-05 | 6.93e-04 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CEL | SNV | Missense_Mutation | rs755884951 | c.1709A>G | p.Glu570Gly | p.E570G | | protein_coding | tolerated(0.12) | benign(0) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CEL | SNV | Missense_Mutation | | c.1558N>T | p.Gly520Cys | p.G520C | | protein_coding | tolerated(0.1) | probably_damaging(0.958) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
CEL | SNV | Missense_Mutation | rs752422506 | c.1544N>A | p.Thr515Asn | p.T515N | | protein_coding | tolerated(0.16) | benign(0.203) | TCGA-E2-A1IE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
CEL | SNV | Missense_Mutation | rs746397927 | c.994N>A | p.Asp332Asn | p.D332N | | protein_coding | deleterious(0.04) | possibly_damaging(0.562) | TCGA-E9-A1RC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
CEL | SNV | Missense_Mutation | novel | c.2149N>A | p.Val717Met | p.V717M | | protein_coding | tolerated_low_confidence(0.08) | benign(0.154) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CEL | SNV | Missense_Mutation | rs760144206 | c.730G>A | p.Gly244Ser | p.G244S | | protein_coding | deleterious(0.01) | probably_damaging(0.968) | TCGA-LP-A4AW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CEL | SNV | Missense_Mutation | rs201133893 | c.2171N>A | p.Gly724Glu | p.G724E | | protein_coding | tolerated_low_confidence(1) | benign(0.001) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CEL | SNV | Missense_Mutation | rs202034862 | c.2173N>A | p.Ala725Thr | p.A725T | | protein_coding | deleterious_low_confidence(0.02) | benign(0.219) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CEL | SNV | Missense_Mutation | rs202034862 | c.2173G>C | p.Ala725Pro | p.A725P | | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.644) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR |
CEL | SNV | Missense_Mutation | | c.832N>A | p.Ala278Thr | p.A278T | | protein_coding | deleterious(0) | possibly_damaging(0.89) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | | Bucelipase alfa | | |
1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | | ACTINOMYCIN D | | 2016288 |
1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | | GENISTEIN | GENISTEIN | 10600647 |
1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | | RESVERATROL | RESVERATROL | 16099206 |
1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | | SIMVASTATIN | SIMVASTATIN | 16955753 |
1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | | GELDANAMYCIN | GELDANAMYCIN | 11104697 |
1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | | BILE SALT STIMULATED LIPASE | | |
1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | | Taurocholic Acid | | |